Literature DB >> 33631128

Improving lung health in low-income and middle-income countries: from challenges to solutions.

Jamilah Meghji1, Kevin Mortimer2, Alvar Agusti3, Brian W Allwood4, Innes Asher5, Eric D Bateman6, Karen Bissell7, Charlotte E Bolton8, Andrew Bush9, Bartolome Celli10, Chen-Yuan Chiang11, Alvaro A Cruz12, Anh-Tuan Dinh-Xuan13, Asma El Sony14, Kwun M Fong15, Paula I Fujiwara16, Mina Gaga17, Luis Garcia-Marcos18, David M G Halpin19, John R Hurst20, Shamanthi Jayasooriya21, Ajay Kumar16, Maria V Lopez-Varela22, Refiloe Masekela23, Bertrand H Mbatchou Ngahane24, Maria Montes de Oca25, Neil Pearce26, Helen K Reddel27, Sundeep Salvi28, Sally J Singh29, Cherian Varghese30, Claus F Vogelmeier31, Paul Walker32, Heather J Zar33, Guy B Marks34.   

Abstract

Low-income and middle-income countries (LMICs) bear a disproportionately high burden of the global morbidity and mortality caused by chronic respiratory diseases (CRDs), including asthma, chronic obstructive pulmonary disease, bronchiectasis, and post-tuberculosis lung disease. CRDs are strongly associated with poverty, infectious diseases, and other non-communicable diseases (NCDs), and contribute to complex multi-morbidity, with major consequences for the lives and livelihoods of those affected. The relevance of CRDs to health and socioeconomic wellbeing is expected to increase in the decades ahead, as life expectancies rise and the competing risks of early childhood mortality and infectious diseases plateau. As such, the World Health Organization has identified the prevention and control of NCDs as an urgent development issue and essential to the achievement of the Sustainable Development Goals by 2030. In this Review, we focus on CRDs in LMICs. We discuss the early life origins of CRDs; challenges in their prevention, diagnosis, and management in LMICs; and pathways to solutions to achieve true universal health coverage.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Year:  2021        PMID: 33631128     DOI: 10.1016/S0140-6736(21)00458-X

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  31 in total

1.  The burden and determinants of post-TB lung disease.

Authors:  S G Mpagama; K S Msaji; O Kaswaga; L J Zurba; P M Mbelele; B W Allwood; B-S Ngungwa; R M Kisonga; M Lesosky; J Rylance; K Mortimer
Journal:  Int J Tuberc Lung Dis       Date:  2021-10-01       Impact factor: 2.373

Review 2.  Research Trends on Pulmonary Rehabilitation: A Bibliometric Analysis From 2011 to 2020.

Authors:  Tao Li; Jia Chen
Journal:  Front Med (Lausanne)       Date:  2022-06-06

3.  Community-based asthma assessment in young children: adaptations for a multicentre longitudinal study in South Asia.

Authors:  Mohammad Shahidul Islam; Samin Huq; Steven Cunningham; Jurgen Schwarze; A S M D Ashraful Islam; Mashal Amin; Farrukh Raza; Radanath Satpathy; Pradipta Ranjan Rauta; Salahuddin Ahmed; Hana Mahmood; Genevie Fernandes; Benazir Baloch; Imran Nisar; Sajid Soofi; Pinaki Panigrahi; Sanjay Juvekar; Ashish Bavkedar; Abdullah H Baqui; Senjuti Saha; Harry Campbell; Aziz Sheikh; Harish Nair; Samir K Saha
Journal:  Ther Adv Infect Dis       Date:  2022-07-18

4.  The burden of asthma, hay fever and eczema in adults in 17 countries: GAN Phase I study.

Authors:  Kevin Mortimer; Maia Lesosky; Luis García-Marcos; M Innes Asher; Neil Pearce; Eamon Ellwood; Karen Bissell; Asma El Sony; Philippa Ellwood; Guy B Marks; Antonela Martínez-Torres; Eva Morales; Virginia Perez-Fernandez; Steven Robertson; Charlotte E Rutter; Richard J Silverwood; David P Strachan; Chen-Yuan Chiang
Journal:  Eur Respir J       Date:  2022-09-15       Impact factor: 33.795

5.  Understanding lung health beliefs in low-resource settings.

Authors:  Jennifer M Wang; MeiLan K Han; Wassim W Labaki
Journal:  Lancet Glob Health       Date:  2022-01       Impact factor: 38.927

6.  Clinical standards for the assessment, management and rehabilitation of post-TB lung disease.

Authors:  G B Migliori; F M Marx; N Ambrosino; E Zampogna; H S Schaaf; M M van der Zalm; B Allwood; A L Byrne; K Mortimer; R S Wallis; G J Fox; C C Leung; J M Chakaya; B Seaworth; A Rachow; B J Marais; J Furin; O W Akkerman; F Al Yaquobi; A F S Amaral; S Borisov; J A Caminero; A C C Carvalho; D Chesov; L R Codecasa; R C Teixeira; M P Dalcolmo; S Datta; A-T Dinh-Xuan; R Duarte; C A Evans; J-M García-García; G Günther; G Hoddinott; S Huddart; O Ivanova; R Laniado-Laborín; S Manga; K Manika; A Mariandyshev; F C Q Mello; S G Mpagama; M Muñoz-Torrico; P Nahid; C W M Ong; D J Palmero; A Piubello; E Pontali; D R Silva; R Singla; A Spanevello; S Tiberi; Z F Udwadia; M Vitacca; R Centis; L D Ambrosio; G Sotgiu; C Lange; D Visca
Journal:  Int J Tuberc Lung Dis       Date:  2021-10-01       Impact factor: 3.427

7.  Protocol for a single-centre mixed-method pre-post single-arm feasibility trial of a culturally appropriate 6-week pulmonary rehabilitation programme among adults with functionally limiting chronic respiratory diseases in Malawi.

Authors:  Fanuel Meckson Bickton; Talumba Mankhokwe; Rebecca Nightingale; Cashon Fombe; Martha Mitengo; Langsfield Mwahimba; Wilfred Lipita; Laura Wilde; Ilaria Pina; Zainab K Yusuf; Zahira Ahmed; Martin Kamponda; Felix Limbani; Harriet Shannon; Enock Chisati; Andy Barton; Robert C Free; Michael Steiner; Jesse A Matheson; Adrian Manise; Sally J Singh; Jamie Rylance; Mark Orme
Journal:  BMJ Open       Date:  2022-01-31       Impact factor: 2.692

8.  Early treatment with inhaled budesonide to prevent clinical deterioration in patients with COVID-19.

Authors:  Alvar Agusti; Ferran Torres; Rosa Faner
Journal:  Lancet Respir Med       Date:  2021-04-09       Impact factor: 30.700

Review 9.  Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes.

Authors:  Helen K Reddel; Leonard B Bacharier; Eric D Bateman; Christopher E Brightling; Guy G Brusselle; Roland Buhl; Alvaro A Cruz; Liesbeth Duijts; Jeffrey M Drazen; J Mark FitzGerald; Louise J Fleming; Hiromasa Inoue; Fanny W Ko; Jerry A Krishnan; Mark L Levy; Jiangtao Lin; Kevin Mortimer; Paulo M Pitrez; Aziz Sheikh; Arzu A Yorgancioglu; Louis-Philippe Boulet
Journal:  Eur Respir J       Date:  2021-12-31       Impact factor: 16.671

10.  Low- and middle- income countries have a different illness profile.

Authors:  Harish Gupta; Nitu Nigam; Sudhir K Verma; Satish Kumar
Journal:  J Family Med Prim Care       Date:  2021-11-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.